3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
1
Interventions
Paclitaxel
12
Carboplatin
11
Cisplatin
9
Letrozole
6
Drug Therapy
6
liposomal doxorubicin
5
Megestrol Acetate
4
Bevacizumab
4
spartalizumab
3
Topotecan
3
Taxes
3
Medroxyprogesterone Acetate
3
olaparib
2
niraparib
2
atezolizumab
2
Methotrexate
2
Magnetic Resonance Spectroscopy
2
Imiquimod
2
Hyperthermic Intraperitoneal Chemotherapy
2
Gonadotropin-Releasing Hormone
2
Gemcitabine
2
Doxorubicin
2
1-dodecylpyridoxal
2
trametinib
1
sintilimab
1
saracatinib
1
ricin A-GnRH conjugate
1
pertuzumab
1
pembrolizumab
1
pegfilgrastim
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
abagovomab
×
Gynecologic
×
Clear all
NCT00418574
2011-11-24
MIMOSA
Menarini Group
Phase 2/3
Terminated
888 enrolled
17 charts